SGS Life Science Services Selects Phase Forward as Preferred Partner

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that SGS Life Science Services, a leading Contract Research Organization (CRO), has selected Phase Forward as a preferred partner. As part of the collaboration, SGS Life Science Services will use Phase Forward's InForm(TM) electronic data capture (EDC) product to support the data collection, management and analysis for clinical trials.

SGS Life Science Services is a full-service Contract Research Organization providing services from early-stage clinical development to late-phase clinical trials throughout Europe, North America and Asia. SGS has clinical operations in North America, France, Belgium, Spain and Asia (Thailand, Singapore and India). Since its inception in 1975, SGS has performed over 2,000 clinical trials and manages 100 trials annually. As a result, SGS has developed a wide expertise in a range of therapeutic areas including cardiovascular, central nervous system, infectious disease and respiratory. SGS Life Science Services Biometrics group is one of the largest EU Data Management CROs, processing over 1,000,000 CRF pages each year and offering comprehensive expertise, including in-depth experience in CDISC, and extensive high throughput capabilities.

The selection of the InForm product as SGS' preferred EDC system marks an expansion of SGS Life Science Services' relationship with Phase Forward. SGS currently uses Phase Forward's Clintrial(TM) product, a comprehensive clinical data management and analysis system that integrates both electronically captured and paper-based study data, as well as Phase Forward's Clintrace(TM) software, a highly scalable, adverse event tracking and reporting system. The InForm solution supports thousands of trial sites with near real-time data, providing end-to-end clinical development capabilities designed to improve trial safety, efficiency and cost-effectiveness. While SGS Life Science Services has extensive experience with the InForm software through externally hosted customers, this agreement allows SGS to offer the EDC system as an integral part of the SGS solution set.

"We are pleased to expand our relationship with Phase Forward into a broader partnership with our implementation of InForm," said Florent Hediard, marketing director, SGS Life Science Services. "Time and again, Phase Forward has demonstrated expertise and in-depth knowledge in developing and delivering innovative technology solutions for clinical trials and drug safety. In addition, we were drawn to Phase Forward's global presence and experience, and the company's dedication to quality. This partnership was a natural next step."

"SGS Life Science Services' commitment to excellence mirrors our own high standards," said Bob Weiler, president and chief executive officer, Phase Forward. "The organization has consistently demonstrated its expertise in managing complex, high-volume, globally distributed trials. We look forward to further developing our partnership with additional joint bids, leveraging our respective strengths to provide full-service programs across all phases of the clinical trial process."

About SGS Life Science Services

SGS Life Science Services, a business unit of the SGS Group, has 30 years of experience as a global Contract Research Organization (CRO) providing a large range of services from preclinical activities to Phase I through IV trials, bio-analytical and QC testing. With more than 1,300 employees in LSS and 2,000 trials performed, SGS Life Science Services serves the pharmaceutical, biotechnology and medical device industries. Additional information about SGS is available at www.sgs.com/clinicalresearch.

The SGS Group is the global leader and innovator in inspection, verification, testing and certification services. Founded in 1878, SGS is recognized as the global benchmark in quality and integrity. With more than 48,000 employees, SGS operates a network of more than 1,000 offices and laboratories around the world.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Clintrace(TM)) and applied data standards (WebSDM(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 265 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Merck & Co., Merck Serono, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute and Servier. Additional information about Phase Forward is available at www.phaseforward.com.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, future business and operations plans of Phase Forward customers and partner, and the ability of Phase Forward's customers and partners to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers and partners to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward's customers and partners, the manner in which Phase Forward's customers and partners conduct business and the possibility that their needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.